Mar. 6 at 1:50 PM
$INIS My Overall OpinionINIS (Radnostix) shows some positive momentum: revenue growth, margin expansion, and a pivot to high-potential areas like theranostics and medical devices, which align with aging populations and advances in nuclear medicine. The asset sale could inject significant cash (~6x current cash reserves), potentially funding R&D or debt reduction, and the name change signals a clearer healthcare focus. If executed well, this could position it for profitability in a niche market with barriers to entry (e.g., regulatory expertise).However, it's a highly speculative investment. The company is tiny, with razor-thin profits, heavy debt relative to equity, and a history of losses that could recur if supplies falter or regulations tighten. Liquidity is precarious, and the registration revocation adds red flags—reduced transparency could mean hidden problems or just administrative fallout from the rebrand. At
$0.09/share, it's cheap, but volatility is high, trading volume low,
